Prelude Capital Management, LLC Atreca, Inc. Transaction History

Prelude Capital Management, LLC

  • $1.57 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$1.61 - $5.2 $144,893 - $467,979
-89,996 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$2.87 - $6.29 $258,288 - $566,074
89,996 New
89,996 $273,000

Others Institutions Holding BCEL

# of Institutions
2
Shares Held
30.6K
Call Options Held
0
Put Options Held
0
View Full List

About Atreca, Inc.

BCEL Quotes by TradingView
  • Ticker BCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,876,000
  • Description
  • Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...
More about BCEL
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email